Articles

The agency is expanding the use of a single booster of the Pfizer-BioNTech vaccine to children ages 12–15 and is shortening the time between primary vaccination and booster to at least five months.  

FDA Expands Use of Pfizer-BioNTech COVID-19 Vaccine

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA authorized emergency use of Pfizer’s oral antiviral drug to make the drug available as quickly as possible. 

Here Come the COVID-19 Treatment Options

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

An obvious theme for 2021 has been COVID-19, but the next 12 months will see industry and its people experiencing further change.

Changes Afoot: 2022 Outlook for Pharma and its People

Overall, 2021 proved to be another good year for drug approvals in Europe, albeit with a slight disappointment for Alzheimer’s patients, but what should industry be watching out for in 2022?

Hot Picks for 2022

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

January is the kind of month that can make your head spin.

January Makes Your Head Spin

Moderna’s vaccine is weaker against the Omicron variant, but boosters can increase neutralizing antibody levels by as much as 83-fold.

Moderna Releases New Vaccine Data Concerning Omicron Variant

Sanofi’s acquisition of Amunix will grant access to their promising immuno-oncology pipeline.

Sanofi Acquires Amunix Pharmaceuticals for $1 Billion

Tezpire (tezepelumab-ckko) has been approved as an add-on maintenance treatment for severe asthma.

FDA Approves AstraZeneca and Amgen’s Tezpire

The agency recommended granting conditional marketing authorization for use of Nuvaxovid in people 18 years of age and older.

EMA Recommends Conditional Authorization for Novavax’s COVID-19 Vaccine

Amgen and Syngene International have extended their research collaboration to 2026.

News